Review



apoptosis  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems apoptosis
    Apoptosis, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 21 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apoptosis/product/R&D Systems
    Average 94 stars, based on 21 article reviews
    apoptosis - by Bioz Stars, 2026-03
    94/100 stars

    Images



    Similar Products

    94
    R&D Systems apoptosis
    Apoptosis, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apoptosis/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    apoptosis - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    93
    R&D Systems tnfsf12
    Tnfsf12, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tnfsf12/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    tnfsf12 - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    94
    R&D Systems recombinant mouse tweak standard
    Recombinant Mouse Tweak Standard, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant mouse tweak standard/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    recombinant mouse tweak standard - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    92
    R&D Systems fn14 decoy receptor
    Fig. 4. <t>FN14</t> decoy receptor modulates the cytokine profile in CNV and reduces neovascularization size. (A): Experimental setup. (B): Intravitreal injection of a FN14 decoy receptor compared to PBS (control) significantly reduced CNV size. For statistical analysis, Mann–Whitney U test was applied. Color fundus (CF) and fluo rescence angiography (FA) on d7 of representative eyes of the FN14 decoy receptor (upper panel) and the PBS group (lower panel) as well as confocal microscopy (CM) images of representative lesions (COL4 in red) the size of which approximately corresponds to the mean spot size within the respective group. (C): Protein concentrations of several cytokines on d5 in the RPE of unlasered controls, CNV injected with PBS (CNV) or with FN14 decoy receptor on d1 (CNV + decoy). Data are shown as mean with SEM. For statistical analysis, paired ANOVA adjusting for total protein concentration was applied. *: p < 0.05, ns: not significant.
    Fn14 Decoy Receptor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fn14 decoy receptor/product/R&D Systems
    Average 92 stars, based on 1 article reviews
    fn14 decoy receptor - by Bioz Stars, 2026-03
    92/100 stars
      Buy from Supplier

    94
    R&D Systems mouse recombinant tweak
    Fig. 4. <t>FN14</t> decoy receptor modulates the cytokine profile in CNV and reduces neovascularization size. (A): Experimental setup. (B): Intravitreal injection of a FN14 decoy receptor compared to PBS (control) significantly reduced CNV size. For statistical analysis, Mann–Whitney U test was applied. Color fundus (CF) and fluo rescence angiography (FA) on d7 of representative eyes of the FN14 decoy receptor (upper panel) and the PBS group (lower panel) as well as confocal microscopy (CM) images of representative lesions (COL4 in red) the size of which approximately corresponds to the mean spot size within the respective group. (C): Protein concentrations of several cytokines on d5 in the RPE of unlasered controls, CNV injected with PBS (CNV) or with FN14 decoy receptor on d1 (CNV + decoy). Data are shown as mean with SEM. For statistical analysis, paired ANOVA adjusting for total protein concentration was applied. *: p < 0.05, ns: not significant.
    Mouse Recombinant Tweak, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse recombinant tweak/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    mouse recombinant tweak - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    94
    R&D Systems murine tweak
    FIGURE 6 CD163 prevents pro-inflammatory actions induced by <t>TWEAK.</t> A, Representative western blot analysis of p-p65 and p65 in VSMCs treated with 0% FBS (control), rTW (100 ng/mL) or rTW plus rCD (0.01-0.5 μg/mL). Right panel show the quantification of band densitometry values of p-p65 protein levels expressed in arbitrary units after correction for p65 (loading control). *P < .01 vs Control; †P < .01 vs rTW; Student's t test. B, Relative CCL2, CCL5, ICAM-1, MMP-2, and MMP-9 mRNA expression levels normalized to 18S rRNA of VSMCs treated with rTW (100 ng/mL) or rTW plus rCD (0.01-0.5 μg/mL) during 24 hours. The same cDNA was repeatedly tested for multiple genes. Data represent the mean ± SEM of three independent experiments. *P < .05 vs Control; †P < .05 vs rTW. Student's t test. C, Effect of CD163 on CCL2 and CCL5 secretion induced by TWEAK in VSMCs. VSMCs were incubated with rTW (100 ng/mL) or rTW plus rCD (0.01-0.5 μg/mL) during 24 hours and supernatants were tested by ELISA for CCL2 or CCL5. Data represent the mean ± SEM of six independent experiments; *P < .001 vs control; †P < .001 vs rTW; Student's t test. D, Peritoneal macrophages were seeded in the upper surface of chemotaxis chambers and stimulated with the supernatants of VSMCs treated with 0% FBS (control), rTWEAK (100 ng/mL) or rTW plus rCD (0.1-0.5 μg/mL). Quantification of migrated cells in 10 fields per condition is shown in the right panel. Data represent the mean ± SEM of four independent experiments; *P < .001 vs Control; †P < .001 vs rTW; Student's t test. Scale bars, 50 μm
    Murine Tweak, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine tweak/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    murine tweak - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    Image Search Results


    Fig. 4. FN14 decoy receptor modulates the cytokine profile in CNV and reduces neovascularization size. (A): Experimental setup. (B): Intravitreal injection of a FN14 decoy receptor compared to PBS (control) significantly reduced CNV size. For statistical analysis, Mann–Whitney U test was applied. Color fundus (CF) and fluo rescence angiography (FA) on d7 of representative eyes of the FN14 decoy receptor (upper panel) and the PBS group (lower panel) as well as confocal microscopy (CM) images of representative lesions (COL4 in red) the size of which approximately corresponds to the mean spot size within the respective group. (C): Protein concentrations of several cytokines on d5 in the RPE of unlasered controls, CNV injected with PBS (CNV) or with FN14 decoy receptor on d1 (CNV + decoy). Data are shown as mean with SEM. For statistical analysis, paired ANOVA adjusting for total protein concentration was applied. *: p < 0.05, ns: not significant.

    Journal: Biochimica et biophysica acta. Molecular basis of disease

    Article Title: Comparative transcriptome analysis of human and murine choroidal neovascularization identifies fibroblast growth factor inducible-14 as phylogenetically conserved mediator of neovascular age-related macular degeneration.

    doi: 10.1016/j.bbadis.2022.166340

    Figure Lengend Snippet: Fig. 4. FN14 decoy receptor modulates the cytokine profile in CNV and reduces neovascularization size. (A): Experimental setup. (B): Intravitreal injection of a FN14 decoy receptor compared to PBS (control) significantly reduced CNV size. For statistical analysis, Mann–Whitney U test was applied. Color fundus (CF) and fluo rescence angiography (FA) on d7 of representative eyes of the FN14 decoy receptor (upper panel) and the PBS group (lower panel) as well as confocal microscopy (CM) images of representative lesions (COL4 in red) the size of which approximately corresponds to the mean spot size within the respective group. (C): Protein concentrations of several cytokines on d5 in the RPE of unlasered controls, CNV injected with PBS (CNV) or with FN14 decoy receptor on d1 (CNV + decoy). Data are shown as mean with SEM. For statistical analysis, paired ANOVA adjusting for total protein concentration was applied. *: p < 0.05, ns: not significant.

    Article Snippet: At d1 mice received an intravitreal injection of 4 μg FN14 decoy receptor (1610- TW, R&D Systems) dissolved in 1 μl PBS in one eye and the same volume of PBS in the other eye.

    Techniques: Injection, Control, MANN-WHITNEY, Confocal Microscopy, Protein Concentration

    FIGURE 6 CD163 prevents pro-inflammatory actions induced by TWEAK. A, Representative western blot analysis of p-p65 and p65 in VSMCs treated with 0% FBS (control), rTW (100 ng/mL) or rTW plus rCD (0.01-0.5 μg/mL). Right panel show the quantification of band densitometry values of p-p65 protein levels expressed in arbitrary units after correction for p65 (loading control). *P < .01 vs Control; †P < .01 vs rTW; Student's t test. B, Relative CCL2, CCL5, ICAM-1, MMP-2, and MMP-9 mRNA expression levels normalized to 18S rRNA of VSMCs treated with rTW (100 ng/mL) or rTW plus rCD (0.01-0.5 μg/mL) during 24 hours. The same cDNA was repeatedly tested for multiple genes. Data represent the mean ± SEM of three independent experiments. *P < .05 vs Control; †P < .05 vs rTW. Student's t test. C, Effect of CD163 on CCL2 and CCL5 secretion induced by TWEAK in VSMCs. VSMCs were incubated with rTW (100 ng/mL) or rTW plus rCD (0.01-0.5 μg/mL) during 24 hours and supernatants were tested by ELISA for CCL2 or CCL5. Data represent the mean ± SEM of six independent experiments; *P < .001 vs control; †P < .001 vs rTW; Student's t test. D, Peritoneal macrophages were seeded in the upper surface of chemotaxis chambers and stimulated with the supernatants of VSMCs treated with 0% FBS (control), rTWEAK (100 ng/mL) or rTW plus rCD (0.1-0.5 μg/mL). Quantification of migrated cells in 10 fields per condition is shown in the right panel. Data represent the mean ± SEM of four independent experiments; *P < .001 vs Control; †P < .001 vs rTW; Student's t test. Scale bars, 50 μm

    Journal: The FASEB Journal

    Article Title: CD163 deficiency increases foam cell formation and plaque progression in atherosclerotic mice

    doi: 10.1096/fj.202000177r

    Figure Lengend Snippet: FIGURE 6 CD163 prevents pro-inflammatory actions induced by TWEAK. A, Representative western blot analysis of p-p65 and p65 in VSMCs treated with 0% FBS (control), rTW (100 ng/mL) or rTW plus rCD (0.01-0.5 μg/mL). Right panel show the quantification of band densitometry values of p-p65 protein levels expressed in arbitrary units after correction for p65 (loading control). *P < .01 vs Control; †P < .01 vs rTW; Student's t test. B, Relative CCL2, CCL5, ICAM-1, MMP-2, and MMP-9 mRNA expression levels normalized to 18S rRNA of VSMCs treated with rTW (100 ng/mL) or rTW plus rCD (0.01-0.5 μg/mL) during 24 hours. The same cDNA was repeatedly tested for multiple genes. Data represent the mean ± SEM of three independent experiments. *P < .05 vs Control; †P < .05 vs rTW. Student's t test. C, Effect of CD163 on CCL2 and CCL5 secretion induced by TWEAK in VSMCs. VSMCs were incubated with rTW (100 ng/mL) or rTW plus rCD (0.01-0.5 μg/mL) during 24 hours and supernatants were tested by ELISA for CCL2 or CCL5. Data represent the mean ± SEM of six independent experiments; *P < .001 vs control; †P < .001 vs rTW; Student's t test. D, Peritoneal macrophages were seeded in the upper surface of chemotaxis chambers and stimulated with the supernatants of VSMCs treated with 0% FBS (control), rTWEAK (100 ng/mL) or rTW plus rCD (0.1-0.5 μg/mL). Quantification of migrated cells in 10 fields per condition is shown in the right panel. Data represent the mean ± SEM of four independent experiments; *P < .001 vs Control; †P < .001 vs rTW; Student's t test. Scale bars, 50 μm

    Article Snippet: For experimental analysis, cells were made quiescent by 24-hour incubation in medium without FBS before stimulation with recombinant murine TWEAK (0.1 μg/mL; 1237-TW; R&D Systems) and preincubated or not with different concentrations of rCD163 (7435-CD; R&D Systems).

    Techniques: Western Blot, Control, Expressing, Incubation, Enzyme-linked Immunosorbent Assay, Chemotaxis Assay